Europäisches Patentamt
European Patent Office
Office européen des brevets

SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application number:
EP 18 84 84 23

Classification of the application (IPC):
C07K 16/28*, *C07K 16/46

Technical fields searched (IPC):
C07K

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim
A	**MAELIG G. MORVAN ET AL**: "NK cells and cancer: you can teach innate cells new tricks" *NATURE REVIEWS CANCER* London 01 January 2016 (2016-01-01), vol. 16, no. 1, DOI: 10.1038/nrc.2015.5, ISSN: 1474-175X, pages 7-19, XP055484885	1-17
A	**GERMAIN CLAIRE ET AL**: "MHC Class I-Related Chain a Conjugated to Antitumor antibodies Can Sensitize Tumor Cells to Specific Lysis by Natural Killer Cell" *CLINICAL CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US*, 15 October 2005 (2005-10-15), vol. 11, no. 20, DOI: 10.1158/1078-0432.CCR-05-0872, ISSN: 1078-0432, pages 7516-7522, XP008084621	1-17
X	WO 2007002905 A1 (UNIV MIAMI [US]; SHIN SEUNG-UON [US] ET AL.) 04 January 2007 (2007-01-04) * paragraphs [0012], [0013], [0060], [0061], [0065], [0066] *	1-17
A	**CHRISTIAN KELLNER ET AL**: "Promoting natural killer cell functions by recombinant immunoligands mimicking an induced self phenotype" *ONCOIMMUNOLOGY* US 27 June 2013 (2013-06-27), vol. 2, no. 6, DOI: 10.4161/onci.24481, ISSN: 2162-4011, page e24481, XP055684159	1-17
A	**Fred Hutchinson Cancer ET AL**: "Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study Correspondence to" *The Lancet*, 27 April 2015 (2015-04-27), pages 704-715 URL: http://www.sciencedirect.com/science/article/pii/S1470204515701282/pdfft?md5=2f9c9cb53dde7a4c2f0b5382bddfd5cf&pid=1-s2.0-S1470204515701282-main.pdf , DOI: 10.1016/S1470-2045(15)70128-2 [retrieved on 08 February 2016 (2016-02-08)] XP055248305	1-17

The supplementary search report has been based on the last set of claims valid and available at the start of the search.

Place of search	Date of completion of the search	Examiner
Munich	11 September 2021	Marinoni J-C

CATEGORY OF CITED DOCUMENTS

X: particularly relevant if taken alone
Y : particularly relevant if combined with another document of the same category
A: technological background
O: non-written disclosure
P: intermediate document
T: theory or principle underlying the invention
E: earlier patent document, but published on, or after the filing date
D: document cited in the application
L: document cited for other reasons
& : member of the same patent family, corresponding document

EP 3 672 993 A4

Europäisches Patentamt
European Patent Office
Office européen des brevets

SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application number:
EP 18 84 84 23

DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim
A	**B. ZHENG ET AL**: "In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates" *MOLECULAR CANCER THERAPEUTICS* US 01 October 2009 (2009-10-01), vol. 8, no. 10, DOI: 10.1158/1535-7163.MCT-09-0369, ISSN: 1535-7163, pages 2937-2946, XP055247619	1-17
A	**PLITAS GEORGE ET AL**: "Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer" *IMMUNITY, CELL PRESS, AMSTERDAM, NL*, 15 November 2016 (2016-11-15), vol. 45, no. 5, DOI: 10.1016/J.IMMUNI. 2016.10.032, ISSN: 1074-7613, pages 1122-1134, XP029809259	1-17
A	**ERUSLANOV ET AL**: "Expansion of CCR8+ Inflammatory Myeloid Cells in Cancer Patients with Urothelial and Renal Carcinomas" *CLIN. CANCER RES.*, 30 January 2013 (2013-01-30), vol. 19, no. 7, DOI: 10.1158/1078-0432.CCR-12-2091, pages 1670-1680, XP055739724	1-17
A	**Jim Stallard**: "New Approach Could Boost Immunotherapy for Breast Cancer" *Memorial Sloan Kettering Cancer Center*, 29 November 2016 (2016-11-29), pages 1-5 URL: https://www.mskcc.org/news/new-approach-could-boost-immunotherapy-for-breast-cancer#:~:text=Researchers%20hope%20targeting%20regulatory%20T,breast%20cancer%20than%20other%20cancers. [retrieved on 26 January 2021 (2021-01-26)] XP055768936	1-17

The supplementary search report has been based on the last set of claims valid and available at the start of the search.

Place of search	Date of completion of the search	Examiner
Munich	11 September 2021	Marinoni J-C

CATEGORY OF CITED DOCUMENTS

X: particularly relevant if taken alone
Y : particularly relevant if combined with another document of the same category
A: technological background
O: non-written disclosure
P: intermediate document
T: theory or principle underlying the invention
E: earlier patent document, but published on, or after the filing date
D: document cited in the application
L: document cited for other reasons

& : member of the same patent family, corresponding document

EP 3 672 993 A4

Europäisches Patentamt
European Patent Office
Office européen des brevets

SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application number:
EP 18 84 84 23

LACK OF UNITIY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. claims: 8, 9(completely); 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen CD79b; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

2. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen CXCR4; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

3. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen CD25; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

4. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen VLA4; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

5. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen CD44; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

6. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen CD13; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

7. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen CD15; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

8. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen CD47; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

9. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen CD81; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

The supplementary search report has been based on the last set of claims valid and available at the start of the search.

Place of search	Date of completion of the search	Examiner
Munich	11 September 2021	Marinoni J-C

CATEGORY OF CITED DOCUMENTS

X: particularly relevant if taken alone
Y : particularly relevant if combined with another document of the same category
A: technological background
O: non-written disclosure
P: intermediate document
T: theory or principle underlying the invention
E: earlier patent document, but published on, or after the filing date
D: document cited in the application
L: document cited for other reasons
& : member of the same patent family, corresponding document

EP 3 672 993 A4

Europäisches Patentamt
European Patent Office
Office européen des brevets

SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application number:
EP 18 84 84 23

LACK OF UNITIY OF INVENTION

10. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen CD23; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

11. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen CD40; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

12. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen CD70; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

13. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen CD79a; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

14. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen CD80; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

15. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen CRLF2; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

16. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen SLAMF7; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

17. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen CD138; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

18. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen CD38; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

19. claims: 1-7, 10-17(all partially)

The supplementary search report has been based on the last set of claims valid and available at the start of the search.

Place of search	Date of completion of the search	Examiner
Munich	11 September 2021	Marinoni J-C

CATEGORY OF CITED DOCUMENTS

X: particularly relevant if taken alone
Y : particularly relevant if combined with another document of the same category
A: technological background
O: non-written disclosure
P: intermediate document
T: theory or principle underlying the invention
E: earlier patent document, but published on, or after the filing date
D: document cited in the application
L: document cited for other reasons
& : member of the same patent family, corresponding document

EP 3 672 993 A4

Europäisches Patentamt
European Patent Office
Office européen des brevets

SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application number:
EP 18 84 84 23

LACK OF UNITIY OF INVENTION

A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen TRBC1; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

20. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen TRBC2; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

21. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen LILRB2; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

22. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen LILRB1; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

23. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen LILRB3; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

24. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen LILRB4; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

25. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen LILRB5; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

26. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen LILRA1; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

27. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen LILRA2; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

28. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen LILRA3; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

The supplementary search report has been based on the last set of claims valid and available at the start of the search.

Place of search	Date of completion of the search	Examiner
Munich	11 September 2021	Marinoni J-C

CATEGORY OF CITED DOCUMENTS

X: particularly relevant if taken alone
Y : particularly relevant if combined with another document of the same category
A: technological background
O: non-written disclosure
P: intermediate document
T: theory or principle underlying the invention
E: earlier patent document, but published on, or after the filing date
D: document cited in the application
L: document cited for other reasons
& : member of the same patent family, corresponding document

EP 3 672 993 A4

Europäisches Patentamt
European Patent Office
Office européen des brevets

SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application number:
EP 18 84 84 23

LACK OF UNITIY OF INVENTION

29. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen LILRA4; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

30. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen LILRA5; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

31. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen LILRA6; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

32. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen CCR8; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

33. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen CD7; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

34. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen CTLA4; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

35. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen ENRPD1; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

36. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen HAVCR2; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

37. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen IL-1R2; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

38. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen PDCD1 LG2; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

The supplementary search report has been based on the last set of claims valid and available at the start of the search.

Place of search	Date of completion of the search	Examiner
Munich	11 September 2021	Marinoni J-C

CATEGORY OF CITED DOCUMENTS

X: particularly relevant if taken alone
Y : particularly relevant if combined with another document of the same category
A: technological background
O: non-written disclosure
P: intermediate document
T: theory or principle underlying the invention
E: earlier patent document, but published on, or after the filing date
D: document cited in the application
L: document cited for other reasons

& : member of the same patent family, corresponding document

EP 3 672 993 A4

Europäisches Patentamt
European Patent Office
Office européen des brevets

SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application number:
EP 18 84 84 23

LACK OF UNITIY OF INVENTION

39. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen TIGIT; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

40. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen TNFRSF4; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

41. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen TNFRSF8; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

42. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen TNFRSF9; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

43. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen GEM; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

44. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen NT5E; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

45. claims: 1-7, 10-17(all partially)
A protein comprising (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds the tumour-associated antigen TNFRSF18; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD 16, or a third antigen-binding site that binds CD 16, and related subject-matter.

Only part of the further search fees have been paid within the fixed time limit. The present (supplementary) European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims: 8, 9(completely); 1-7, 10-17(partially)

The supplementary search report has been based on the last set of claims valid and available at the start of the search.

Place of search	Date of completion of the search	Examiner
Munich	11 September 2021	Marinoni J-C

CATEGORY OF CITED DOCUMENTS

X: particularly relevant if taken alone
Y : particularly relevant if combined with another document of the same category
A: technological background
O: non-written disclosure
P: intermediate document
T: theory or principle underlying the invention
E: earlier patent document, but published on, or after the filing date
D: document cited in the application
L: document cited for other reasons

& : member of the same patent family, corresponding document

EP 3 672 993 A4

Europäisches Patentamt
European Patent Office
Office européen des brevets

ANNEX TO SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application number:
EP 18 84 84 23

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on 11-09-2021
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2007002905 A1	04-01-2007	EP 1909832 A1	16-04-2008
		JP 2009500346 A	08-01-2009
		US 2007071759 A1	29-03-2007
		WO 2007002905 A1	04-01-2007

EP 3 672 993 A4